The offering provides a capital lifeline but at significant dilution for a $2M market cap company. Monitor the size of the offering when disclosed (likely in a subsequent 8-K or prospectus) and the company's cash runway. The stock may face downward pressure from the dilutive issuance and potential resale registration.
Price Chart
Executive Summary
CNS Pharmaceuticals entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants at $2.30 per share, with A.G.P./Alliance Global Partners as placement agent. The company also filed a registration rights agreement, pre-funded warrant form, and placement agency agreement. The offering is dilutive and signals capital needs for a micro-cap biotech with a $2M market cap, but the exact number of shares and total proceeds are undisclosed.
Key Facts
- Securities Purchase Agreement dated May 4, 2026 for private placement of common stock and pre-funded warrants at $2.30/share
- Placement agent is A.G.P./Alliance Global Partners with a 7.0% cash fee on gross proceeds
- Registration Rights Agreement requires filing of resale registration statement within 15 days of closing and effectiveness within 60-90 days
- Pre-funded warrants have a nominal exercise price of $0.001 per share
- Company has a market cap of only $2M and is a pre-revenue biotech
- Lock-up agreements required from executive officers and directors
- Company restricted from issuing variable rate transactions for one year and from most equity issuances for 120 days post-effectiveness
Financial Impact
Undisclosed total proceeds; $2.30/share price; 7% placement agent fee; $75,000 reimbursement for lead purchaser counsel
Risk Factors
- Dilution from new shares and pre-funded warrants
- Potential for further capital raises given micro-cap status and pre-revenue stage
- Risk of Nasdaq delisting if minimum bid price or market cap requirements not met
- Registration of resale shares could lead to overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-003432 |
| Document: cns_ex1002.htm | 0001683168-26-003432 |
| Document: cns_ex0401.htm | 0001683168-26-003432 |
| Document: cns_ex0101.htm | 0001683168-26-003432 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $5.32 | awaiting T+20 | — | $4.63 (−13.14%) |
Jul 2, 2026 16w ago | 8-K | $5.07 $4.85 | ▼ −4.34% | ▼ −3.92% | $4.63 (−8.78%) |
May 27, 2026 21w ago | EFFECT | $5.12 $4.15 | ▲ +18.91% | ▲ +17.01% | $4.63 (+9.67%) |
May 19, 2026 22w ago | S-3 | $5.10 $4.70 | ▲ +7.84% | ▲ +8.58% | $4.63 (+9.31%) |
May 4, 2026 25w ago | 8-K | $7.84 $5.03 | ▲ +35.84% | ▲ +41.49% | $4.63 (+41.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers